Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

234.13 -1.25 (-0.53%)

Streaming Delayed Price Updated: 1:04 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

NASDAQ:JAZZ is probably undervalued for the fundamentals it is displaying. ↗

February 19, 2025

JAZZ PHARMACEUTICALS PLC may be an undervalued stock option. NASDAQ:JAZZ retains a strong financial foundation and an attractive price tag.

Via Chartmill

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

February 13, 2025

Via Benzinga

Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) ↗

February 13, 2025

Via Benzinga

Investors should take notice of NASDAQ:JAZZ—it offers a great deal for the fundamentals it presents. ↗

January 29, 2025

When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

NASDAQ:JAZZ, an undervalued stock with good fundamentals. ↗

January 08, 2025

Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents.

Via Chartmill

NASDAQ:JAZZ is an undervalued gem with solid fundamentals. ↗

December 17, 2024

Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents.

Via Chartmill

NASDAQ:JAZZ, an undervalued stock with good fundamentals. ↗

November 04, 2024

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ): good value for what you're paying.

Via Chartmill

In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals ↗

October 23, 2024

Via Benzinga

Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts ↗

October 04, 2024

Via Benzinga

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements ↗

December 09, 2024

The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and...

Via Benzinga

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says ↗

November 27, 2024

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

Via Benzinga

NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

November 25, 2024

For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals.

Via Chartmill

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework ↗

November 21, 2024

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

Via Benzinga

UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy ↗

November 08, 2024

Via Benzinga

Topics Cannabis

Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued. ↗

September 19, 2024

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.

Via Chartmill

A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals ↗

September 09, 2024

Via Benzinga

A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals ↗

August 19, 2024

Via Benzinga

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth? ↗

November 06, 2024

CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.

Via Benzinga

Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker ↗

October 18, 2024

Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!

Via The Motley Fool

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer ↗

October 15, 2024

Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a...

Via Benzinga

NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

October 14, 2024

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.

Via Chartmill

FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms ↗

September 19, 2024

Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them.

Via Benzinga

Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals ↗

August 01, 2024

Via Benzinga

When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

August 29, 2024

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.

Via Chartmill

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices ↗

August 28, 2024

Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and...

Via Benzinga

'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine ↗

August 27, 2024

Via Benzinga

The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal ↗

August 23, 2024

Via Benzinga

In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals. ↗

August 08, 2024

Don't overlook JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

The 3 Best Cannabis Stocks to Buy in August 2024 ↗

August 05, 2024

Although cannabis stocks have been brutalized earlier, favorable legal winds could make the sector intriguing again.

Via InvestorPlace

Topics Cannabis

3 Biotech Stocks to Buy on the Dip: July 2024 ↗

July 29, 2024

Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.